Zydus Lifesciences Limited has signed an exclusive agreement with Myriad Genetics, a leader in molecular diagnostic testing and precision medicine, to launch cancer-risk assessment diagnostic tests in India. The partnership was announced through a press release dated December 19, 2025.

Agreement Details

Under the exclusive agreement, Zydus will introduce three key diagnostic tests to the Indian market:

These globally trusted tests have been widely adopted in North America, Europe, and major global cancer centres, and will now empower Indian oncologists with cutting-edge genomic decision-support tools.

Test Specifications and Applications

The MyRisk Test analyzes 63 clinically significant genes including BRCA1, BRCA2, PALB2, ATM, TP53, MLH1, and MSH2, covering cancer types like breast, ovarian, lung, pancreatic, colorectal, endometrial, prostate, gastric, and melanoma. The test includes a Risk Score that combines genetic and clinical data to predict 5-year and lifetime breast cancer risk.

The MyChoice HRD Plus Test determines HRD status based on genomic alterations in BRCA1 and BRCA2 genes and Genomic Instability Score using Myriad's proprietary algorithm. This enables healthcare professionals to identify patients with advanced ovarian cancer who are more likely to respond to targeted therapies.

The Prolaris Test is an RNA-based gene expression test that quantifies tumour aggressiveness and provides patient-specific risk scores, helping clinicians determine treatment approaches and 10-year risk of metastasis.

Management Commentary

Dr. Sharvil P. Patel, Managing Director of Zydus, stated that the agreement marks a major step in expanding access to precision diagnostic tests for cancer treatment in India. He emphasized that the tests will help doctors develop personalized treatment plans, predict disease progression, and streamline clinical workflows.

"This collaboration with Myriad Genetics will strengthen clinician education and diagnostic infrastructure so that patients benefit from earlier, more accurate risk assessment and more confident treatment planning," Dr. Patel added.

Brian Donnelly, Chief Commercial Officer for Myriad Genetics, described the collaboration as an important step forward in expanding precision oncology across India, noting that Myriad tests aim to empower clinicians with actionable information for personalized care.

Market Impact

The partnership addresses the increasing incidence of cancers globally and in India specifically. With rising prostate cancer incidence in India, the Prolaris Test offers a clinically validated tool for personalized therapy decisions. The collaboration is expected to make personalized, evidence-based cancer care accessible to patients across India's healthcare system.

Zydus Life Science , a prominent player in the pharmaceutical industry, has announced the passing of Mr. Samir Desai, President-BU Biologics and a key member of the company's senior management. The company informed the stock exchanges BSE and NSE about this development on August 26, 2025.

Senior Management Change

Mr. Samir Desai, who held the position of President-BU Biologics at Zydus Lifesciences, passed away on August 26, 2025. As a result, he ceases to be part of the company's senior management team. The company expressed profound grief in its communication to the stock exchanges.

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zydus Lifesciences provided the necessary details regarding this change in senior management.

Enhanced ESG Rating Performance

Zydus Lifesciences has received an improved Environmental, Social, and Governance (ESG) score for the financial year 2024-2025. SES ESG Research Private Limited has assigned the company an ESG score of 69.4, representing an improvement from the previous year's score of 67.8.

According to the rating framework, a score ranging between 60-70 is categorized as Medium Risk. The company noted that this rating was unsolicited, indicating an independent assessment of its ESG practices.

Regulatory Compliance and Disclosure

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences, signed the communications to the stock exchanges. The ESG rating disclosure was made in compliance with Regulation 30 of the Listing Regulations, read with SEBI Circulars dated November 11, 2024, and December 31, 2024.

The company ensured timely disclosure of these significant events, maintaining transparency with its stakeholders and complying with regulatory requirements. While Zydus Lifesciences faces the challenge of losing a key member of its senior management team, the improved ESG score indicates the company's ongoing efforts to enhance its sustainability and governance practices.